Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol or Febuxostat for CI-AKI Prevention
NCT03767322Phase 2
Key facts
- Status
- Unknown
- Start
- Dec 2018
- Primary completion
- Oct 2019
- Countries
- 1
- Sponsor
- Instituto Nacional de Cardiología Ignacio Chávez
- Modality
- Small Molecules
- Conditions
- contrast-induced acute kidney injury (CI-AKI)
01
Overview
Phase 2, randomised, double-blind trial in contrast-induced acute kidney injury (CI-AKI) comparing Allopurinol group, Febuxostat group and Placebo group (3 arms). Primary endpoint: Prevention of contrast induced acute kidney injury at 48 hours. Status: unknown.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Allopurinol group
Allopurinol 300 mg
Febuxostat group
Febuxostat 80 mg
Placebo group
Placebo
03
Endpoints
Primary
Prevention of contrast induced acute kidney injury
Secondary
Renal replacement therapy requirement
Length of hospitalization
Beyond the preview
Go deeper on NCT03767322.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767322.